Spinocerebellar Ataxia Type 3 Clinical Trial
Official title:
A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia
The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.
Status | Not yet recruiting |
Enrollment | 45 |
Est. completion date | December 31, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 60 Years |
Eligibility | Inclusion Criteria: - Clinical and genomic test diagnoses as spinocerebellar ataxias (SCA) (include SCA 1, SCA 2, SCA 3, SCA 6), SARA (Scale for Assessment and Rating of Ataxia) score is 2-5, can complete 8-meter walking test(8MW) - Do not receive stem cells treatment in 6 months - Participants sign the consent form based on the experiment process and statement Exclusion Criteria: - Cardiac, renal, hepatic insufficiency; total bilirubin is 1.5 times higher than normal value, aspartate transaminase(AST)or alanine aminotransferase(ALT)is 2.5 times higher than normal value - Hemogram: total white blood cells <3.0 * 10^9 cells/L, blood platelet <75 * 10^9/L, hemoglobin <100g/L - pneumonia, or severe infection - With severe allergic history - Brain organic disorder, like brain tumor - Serum with HIV, syphilis antibody positive - Severe mental disease, cognitive disorder patients - Other severe system or organ organic disease - Pregnant, breast feeding, or planning pregnant women - Participate other clinical experiments in 3 months - With some other conditions that doctor propose not to participate |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sclnow Biotechnology Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scale for the assessment anf rating of ataxia (SARA) | Based on SARA score to calculate treatment efficacy. The equation is as follow, Efficacy = (patients who accepted treatment are effective/patients who accepted treatment)* 100% Effective: after 12 months, score of patient decrease 1 point or more; Ineffective: after 12 months, score decrease less than 1 point or increase. | 12 months | |
Secondary | Image examinations | MRI plain scan of brain. | 12 months | |
Secondary | Inventory of Non-Ataxia Symptoms (INAS) score | Using Inventory of Non-Ataxia Symptoms (INAS) score to determine the presence and severity of non-ataxia signs. | 12 months | |
Secondary | Cerebrospinal fluid (csf) routine | Patients is observed by professionals, compare the changes of each observation point and baseline. Baseline is the data acquire from patients before stem cells treatment. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00992771 -
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Completed |
NCT01096082 -
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Active, not recruiting |
NCT04229823 -
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
|
||
Active, not recruiting |
NCT04419974 -
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
|
||
Terminated |
NCT05490563 -
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Withdrawn |
NCT01096095 -
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Active, not recruiting |
NCT05826171 -
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
|
N/A | |
Recruiting |
NCT04399265 -
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
|
N/A | |
Completed |
NCT03885167 -
Identification of Biomarkers in Spinocerebellar Ataxia 3
|
||
Terminated |
NCT05160558 -
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
|
Phase 1 | |
Recruiting |
NCT05822908 -
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
|
Phase 1/Phase 2 | |
Completed |
NCT05502432 -
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
|
N/A | |
Recruiting |
NCT04714307 -
Neuropsychiatry and Cognition in SCA3/MJD
|
||
Recruiting |
NCT05557786 -
Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
|
||
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|